Thermo Fisher intends to use the proceeds to redeem the outstanding $900 million aggregate principal amount of its 3.20 percent senior notes that mature in March.
Net proceeds from the offering are expected to be $1.98 billion, which will be used to repay part of the financing that went toward Danaher's buy of Pall.
The notes, due in 2022, were priced at 99.788 percent of the principal amount, with their issuance expected to close on or about July 21.
Proceeds from the notes offering will be used to pay a portion of the $13.8 billion cost of acquiring Pall.
Proceeds from the offering will be used to redeem $400 million of senior subordinated notes due in 2018.
Proceeds from the offering will be used to redeem its outstanding 6.25 percent senior notes due 2020 in the aggregate principal amount of $1 billion.
The firm will use proceeds from the private offering to redeem outstanding notes due 2020.
Proceeds from the offering will be used to redeem $400 million outstanding in senior notes due 2018.
The firm privately negotiated the exchange with current holders of convertible notes due 2017.
The firm will use the funds to purchase outstanding debt and redeem certain series of senior notes.
Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.
Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.
The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.
In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.